CA2069900A1 - Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor - Google Patents

Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor

Info

Publication number
CA2069900A1
CA2069900A1 CA002069900A CA2069900A CA2069900A1 CA 2069900 A1 CA2069900 A1 CA 2069900A1 CA 002069900 A CA002069900 A CA 002069900A CA 2069900 A CA2069900 A CA 2069900A CA 2069900 A1 CA2069900 A1 CA 2069900A1
Authority
CA
Canada
Prior art keywords
erbb
egf
human
growth factor
epidermal growth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002069900A
Other languages
French (fr)
Other versions
CA2069900C (en
Inventor
Matthias H. Kraus
Stuart A. Aaronson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
Matthias H. Kraus
Stuart A. Aaronson
The United States Of America, Represented By The Secretary, U.S. Departm Ent Of Commerce
The Government Of The United States Of America, As Represented By The Se Cretary, Department Of Health And Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Matthias H. Kraus, Stuart A. Aaronson, The United States Of America, Represented By The Secretary, U.S. Departm Ent Of Commerce, The Government Of The United States Of America, As Represented By The Se Cretary, Department Of Health And Human Services filed Critical Matthias H. Kraus
Publication of CA2069900A1 publication Critical patent/CA2069900A1/en
Application granted granted Critical
Publication of CA2069900C publication Critical patent/CA2069900C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5748—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Abstract

A DNA fragment distinct from the epidermal growth factor receptor (EGF-R) and erbB-2 genes was detected by reduced stringency hybridization of v-erbB to normal genomic human DNA.
Characterization of the cloned DNA fragment mapped the region of v-erbB homology to three exons with closest homology of 64 % and 67 % to a contiguous region within the tyrosine kinase domains of the EGF-R and erbB-2 proteins, respectively, cDNA cloning revealed a predicted 148 kd transmembrane polypeptide with structural features identifying it as a member of the erbB
family, prompting designation of the new gene as erbB-3.
It was mapped to human chromosome 12q11-13 and was shown to be expressed as 6.2 kb transcript in a variety of normal tissues of epithelial origin. Markedly elevated erbB-3 mRNA levels were demonstrated in certain human mammary tumor cell lines.
These findings indicate that increased erbB-3 expression, as in the case of EGF-R and erbB-2, plays a role in some human malignancies.
CA002069900A 1989-12-01 1990-11-30 Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor Expired - Lifetime CA2069900C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US444,406 1989-12-01
US07/444,406 US5183884A (en) 1989-12-01 1989-12-01 Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
PCT/US1990/007025 WO1991008214A1 (en) 1989-12-01 1990-11-30 Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor

Publications (2)

Publication Number Publication Date
CA2069900A1 true CA2069900A1 (en) 1991-06-02
CA2069900C CA2069900C (en) 2004-07-27

Family

ID=23764745

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002069900A Expired - Lifetime CA2069900C (en) 1989-12-01 1990-11-30 Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor

Country Status (10)

Country Link
US (6) US5183884A (en)
EP (1) EP0502927B1 (en)
JP (2) JP3196079B2 (en)
AT (1) ATE163970T1 (en)
AU (1) AU654805B2 (en)
CA (1) CA2069900C (en)
DE (1) DE69032133T2 (en)
DK (1) DK0502927T3 (en)
ES (1) ES2113877T3 (en)
WO (1) WO1991008214A1 (en)

Families Citing this family (182)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0474727B1 (en) * 1989-05-19 1997-07-23 Genentech, Inc. Her2 extracellular domain
US5183884A (en) * 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
US5578482A (en) * 1990-05-25 1996-11-26 Georgetown University Ligand growth factors that bind to the erbB-2 receptor protein and induce cellular responses
US6824777B1 (en) * 1992-10-09 2004-11-30 Licentia Ltd. Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy
US6107046A (en) * 1992-10-09 2000-08-22 Orion Corporation Antibodies to Flt4, a receptor tyrosine kinase and uses thereof
US5776755A (en) * 1992-10-09 1998-07-07 Helsinki University Licensing, Ltd. FLT4, a receptor tyrosine kinase
US5811098A (en) * 1992-11-24 1998-09-22 Bristol-Myers Squibb Company Antibodies to HER4, human receptor tyrosine kinase
WO1995002057A1 (en) * 1993-07-09 1995-01-19 The Institute Of Cancer Research Protein tyrosine kinase and ligands thereof
KR100355111B1 (en) * 1993-10-27 2003-03-03 더 트러스티스 오브 컬럼비아 유니버시티 인 더 시티 오브 뉴욕 Extraction cDNA Library Manufacturing Method and Uses of Manufactured Library
US5518885A (en) * 1994-04-19 1996-05-21 The United States Of America As Represented By The Department Of Health & Human Services ERBB2 promoter binding protein in neoplastic disease
US5985598A (en) * 1994-10-27 1999-11-16 Thomas Jefferson University TCL-1 gene and protein and related methods and compositions
US7175995B1 (en) 1994-10-27 2007-02-13 Thomas Jefferson University TCL-1 protein and related methods
EP1353952B1 (en) * 1994-11-14 2007-04-11 Ludwig Institute For Cancer Research Flt4(vegfr-3) as a target for tumor imaging and anti-tumor therapy
US5635351A (en) * 1995-03-14 1997-06-03 The Regents Of The University Of California Genetic gain and loss in gliomas
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
ES2274537T5 (en) * 1996-03-27 2015-09-14 Genentech, Inc. ErbB3 antibodies
US5968511A (en) * 1996-03-27 1999-10-19 Genentech, Inc. ErbB3 antibodies
DK0912734T3 (en) 1996-07-12 2011-02-07 Genentech Inc Chimeric heteromultimer adhesives
DE69732711T2 (en) * 1996-07-12 2006-03-16 Genentech, Inc., South San Francisco GAMMA-heregulin
US5710137A (en) * 1996-08-16 1998-01-20 The Trustees Of Columbia University In The City Of New York Use of a melanoma differentiation associated gene (mda 7) for reversing a cancerous phenotype
US7371376B1 (en) 1996-10-18 2008-05-13 Genentech, Inc. Anti-ErbB2 antibodies
DE69840699D1 (en) * 1997-02-10 2009-05-14 Genentech Inc HEREGULIN VARIANTS
US6136558A (en) * 1997-02-10 2000-10-24 Genentech, Inc. Heregulin variants
EP1690927A1 (en) * 1997-04-30 2006-08-16 Hans Klingemann Natural killer cell lines and methods of use
US7052692B1 (en) 1997-09-02 2006-05-30 Advanced Research & Technology Institute Role of tyrosine phosphorylation of a cellular protein in adeno-associated virus 2-mediated transgene expression
CA2306183A1 (en) 1997-10-29 1999-05-06 Genentech, Inc. Wnt-1 induced secreted polypeptides: wisp-1, -2 and -3
ATE409225T1 (en) 1997-10-29 2008-10-15 Genentech Inc GENES INDUCIBLE BY WNT-1
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
US20010023241A1 (en) * 1998-02-04 2001-09-20 Sliwkowski Mark X. Use of heregulin as a growth factor
EP1941905A1 (en) 1998-03-27 2008-07-09 Genentech, Inc. APO-2 Ligand-anti-her-2 antibody synergism
JP4841724B2 (en) * 1998-10-09 2011-12-21 ベジェニクス ピーティーワイ リミテッド Flt4 (VERG-3) as a target for tumor imaging and anti-tumor therapy
PT1165113E (en) * 1999-04-06 2008-09-23 Genentech Inc Use of erbb receptor ligands in treating diabetes
AUPQ105799A0 (en) * 1999-06-18 1999-07-08 Victor Chang Cardiac Research Institute, The Cell growth inhibition
US6949245B1 (en) * 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
LT2803367T (en) 1999-06-25 2018-03-26 Immunogen, Inc. Methods of treatment using anti-ERBB antibody-maytansinoid conjugates
US20040013667A1 (en) * 1999-06-25 2004-01-22 Genentech, Inc. Treatment with anti-ErbB2 antibodies
US20030086924A1 (en) * 1999-06-25 2003-05-08 Genentech, Inc. Treatment with anti-ErbB2 antibodies
US7041292B1 (en) 1999-06-25 2006-05-09 Genentech, Inc. Treating prostate cancer with anti-ErbB2 antibodies
PT1189634E (en) * 1999-06-25 2007-06-06 Genentech Inc Treating prostate cancer with anti-erbb2 antibodies
DK1189641T5 (en) 1999-06-25 2011-04-11 Genentech Inc Humanized ANTI-ErbB2 antibodies and treatment with ANTI-ErbB2 antibodies
MXPA02002037A (en) 1999-08-27 2002-10-31 Genentech Inc DOSAGES FOR TREATMENT WITH ANTI ErbB2 ANTIBODIES.
US7390632B2 (en) * 1999-09-30 2008-06-24 Tumor Biology Investment Group, Inc. Soluble ErbB3 receptor isoforms
US7892541B1 (en) 1999-09-30 2011-02-22 Tumor Biology Investment Group, Inc. Soluble epidermal growth factor receptor isoforms
EP1229934B1 (en) 1999-10-01 2014-03-05 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
US7097840B2 (en) 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
BR0110610A (en) 2000-04-11 2003-04-29 Genentech Inc Isolated antibodies, immunoconjugates, polypeptide chains, isolated nucleic acid, vector, host cell, antibody or polypeptide chain production process, method of treating mammalian dysfunction, method of inducing apoptosis of a cancer cell, method of killing a cell b, method for killing a cell expressing an erbb receptor and uses of isolated antibodies
WO2001083781A2 (en) * 2000-04-28 2001-11-08 Millennium Pharmaceuticals, Inc. 14094, a novel human trypsin family member and uses thereof
IL152656A0 (en) * 2000-05-19 2003-06-24 Genentech Inc Gene detection assay for improving the likelihood of an effective response to an erbb antagonist cancer therapy
CN1204142C (en) * 2000-06-01 2005-06-01 冯宝章 Antigene V-erb B oligonucleotide and its use
US6277640B1 (en) 2000-07-31 2001-08-21 Isis Pharmaceuticals, Inc. Antisense modulation of Her-3 expression
US20020119148A1 (en) * 2000-09-01 2002-08-29 Gerritsen Mary E. ErbB4 antagonists
AU2002236572A1 (en) * 2000-11-03 2002-05-21 Board Of Regents, The University Of Texas System Methods for detecting the efficacy of anticancer treatments
EP1228766A1 (en) * 2001-01-31 2002-08-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. PYK2 phosphorylation by HER3 induces tumor invasion
JP4398644B2 (en) 2001-04-06 2010-01-13 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルベニア ErbB interfacial peptide mimics and methods of use thereof
WO2002088363A2 (en) * 2001-05-02 2002-11-07 Bayer Healthcare Ag Regulation of novel human prolyl 4-hydroxylases
US7745398B2 (en) * 2001-05-31 2010-06-29 Tumor Biology Investment Group, Inc. Soluble ErbB3 and treatment of cancer
US7612042B2 (en) * 2001-05-31 2009-11-03 Tumor Biology Investment Group, Inc. Methods for inhibiting heregulin and treating cancer
US7744882B2 (en) 2001-05-31 2010-06-29 Tumor Biology Investment Group, Inc. Soluble ErbB3 methods of detection and antibodies
DE10131187C2 (en) * 2001-06-28 2003-06-18 Infineon Technologies Ag Exposure mask with repaired blind structure
WO2003011897A1 (en) * 2001-07-27 2003-02-13 The Regents Of The University Of California Modulation of heregulin and her3 interaction
EP1283053A1 (en) 2001-08-09 2003-02-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibitors of HER3 activity
AU2002326910A1 (en) * 2001-09-14 2003-04-01 Incyte Genomics, Inc. Receptors and membrane-associated proteins
JP2003110360A (en) * 2001-09-28 2003-04-11 Seiko Epson Corp Voltage-controlled oscillator, receiving apparatus, and communications equipment
EP1495123B1 (en) * 2002-03-26 2013-10-30 Zensun (Shanghai) Science and Technology Limited Erbb3 based methods and compositions for treating neoplasms
US7402397B2 (en) 2002-05-21 2008-07-22 Monogram Biosciences, Inc. Detecting and profiling molecular complexes
US20040229294A1 (en) 2002-05-21 2004-11-18 Po-Ying Chan-Hui ErbB surface receptor complexes as biomarkers
US20040229380A1 (en) * 2002-05-21 2004-11-18 Po-Ying Chan-Hui ErbB heterodimers as biomarkers
AU2003233662B2 (en) 2002-05-23 2010-04-01 Trustees Of The University Of Pennsylvania Fas peptide mimetics and uses thereof
ES2376165T3 (en) * 2002-07-15 2012-03-09 F. Hoffmann-La Roche Ag TREATMENT OF THE C�? NCER WITH THE ANTIBODY DIRECTED AGAINST ERBB2 RHUMAB 2C4.
TWI229650B (en) * 2002-11-19 2005-03-21 Sharp Kk Substrate accommodating tray
JP2006516117A (en) * 2002-11-21 2006-06-22 ジェネンテック・インコーポレーテッド Treatment of non-malignant diseases or disorders using anti-ErbB2 antibodies
BRPI0408928A (en) 2003-04-01 2006-09-12 Monogram Biosciences Inc methods to determine a disease situation in a patient, an apoptotic situation of cells in a sample, and a cancer situation in a patient
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
AU2004265226A1 (en) * 2003-05-16 2005-02-24 Receptor Biologix, Inc. Intron fusion proteins, and methods of identifying and using same
US7402398B2 (en) * 2003-07-17 2008-07-22 Monogram Biosciences, Inc. Measuring receptor homodimerization
JP2007502417A (en) * 2003-08-11 2007-02-08 モノグラム バイオサイエンシズ，インコーポレーテッド Detection and characterization of molecular complexes
EP1681983A4 (en) * 2003-10-14 2008-12-10 Monogram Biosciences Inc Receptor tyrosine kinase signaling pathway analysis for diagnosis and therapy
BR122018071808B8 (en) 2003-11-06 2020-06-30 Seattle Genetics Inc conjugate
WO2005099756A2 (en) * 2004-04-08 2005-10-27 Agus David B ErbB ANTAGONISTS FOR PAIN THERAPY
US20060286102A1 (en) * 2004-05-14 2006-12-21 Pei Jin Cell surface receptor isoforms and methods of identifying and using the same
JP5234734B2 (en) 2004-06-01 2013-07-10 ジェネンテック， インコーポレイテッド Antibody-drug conjugates and methods
SV2006002143A (en) * 2004-06-16 2006-01-26 Genentech Inc USE OF AN ANTIBODY FOR THE TREATMENT OF CANCER RESISTANT TO PLATINUM
AU2005287404B2 (en) 2004-07-22 2009-05-07 Genentech, Inc. HER2 antibody composition
EP3088004B1 (en) 2004-09-23 2018-03-28 Genentech, Inc. Cysteine engineered antibodies and conjugates
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
JO3000B1 (en) * 2004-10-20 2016-09-05 Genentech Inc Antibody Formulations.
US7939267B2 (en) * 2004-11-04 2011-05-10 Laboratory Corporation Of America Holdings Detection of activation of endothelial cells as surrogate marker for angiogenesis
KR20070085855A (en) * 2004-12-07 2007-08-27 제넨테크, 인크. Selecting patients for therapy with a her inhibitor
KR20190110637A (en) * 2005-01-21 2019-09-30 제넨테크, 인크. Fixed dosing of her antibodies
WO2006086730A2 (en) * 2005-02-09 2006-08-17 Genentech, Inc. Inhibiting her2 shedding with matrix metalloprotease antagonists
SI1850874T1 (en) * 2005-02-23 2014-01-31 Genentech, Inc. Extending time to disease progression or survival in ovarian cancer patients using pertuzumab
WO2006096861A2 (en) * 2005-03-08 2006-09-14 Genentech, Inc. METHODS FOR IDENTIFYING TUMORS RESPONSIVE TO TREATMENT WITH HER DIMERIZATION INHIBITORS (HDIs)
JP2006316040A (en) 2005-05-13 2006-11-24 Genentech Inc Herceptin(r) adjuvant treatment
US20090170769A1 (en) * 2005-05-13 2009-07-02 Pei Jin Cell surface receptor isoforms and methods of identifying and using the same
AR056857A1 (en) 2005-12-30 2007-10-24 U3 Pharma Ag DIRECTED ANTIBODIES TO HER-3 (RECEIVER OF THE HUMAN EPIDERMAL GROWTH FACTOR-3) AND ITS USES
ES2613957T3 (en) 2006-08-04 2017-05-29 Medimmune Limited Antibodies against ERBB2
EP2097754B2 (en) 2006-11-28 2018-01-24 Daiichi Sankyo Europe GmbH Activated her3 as a marker for predicting therapeutic efficacy
KR101598229B1 (en) * 2007-02-16 2016-02-26 메리맥 파마슈티컬즈, 인크. 3 antibodies against erbb3 and uses thereof
CN103432580A (en) 2007-03-02 2013-12-11 健泰科生物技术公司 Predicting response to a HER dimerisation inhibitor based on low HER3 expression
WO2008118970A2 (en) 2007-03-27 2008-10-02 Sea Lane Biotechnologies, Llc Constructs and libraries comprising antibody surrogate light chain sequences
SI2171090T1 (en) 2007-06-08 2013-07-31 Genentech, Inc. Gene expression markers of tumor resistance to her2 inhibitor treatment
CA2706763C (en) * 2007-11-27 2013-07-30 Laboratory Corporation Of America Holdings Enhanced method for detecting and/or quantifying an analyte in a sample
US10416162B2 (en) * 2007-12-20 2019-09-17 Monogram Biosciences, Inc. Her2 diagnostic methods
KR101640161B1 (en) 2008-01-18 2016-07-15 낫코 파마 리미티드 6,7-dialkoxy quinazoline derivatives useful for treatment of cancer related disorders
TWI472339B (en) 2008-01-30 2015-02-11 Genentech Inc Composition comprising antibody that binds to domain ii of her2 and acidic variants thereof
NZ709293A (en) 2008-03-18 2017-01-27 Genentech Inc Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use
BRPI0812682A2 (en) 2008-06-16 2010-06-22 Genentech Inc metastatic breast cancer treatment
WO2009157919A1 (en) * 2008-06-23 2009-12-30 Tumor Biology Investment Group, Inc. SOLUBLE ErbB3 DETECTION, REGULATION AND TREATMENT OF CANCER
US8623592B2 (en) * 2008-08-15 2014-01-07 Merrimack Pharmaceuticals, Inc. Methods and systems for predicting response of cells to a therapeutic agent
CA2764386C (en) 2008-12-01 2018-05-01 Laboratory Corporation Of America Holdings P95-her2 antibodies and uses thereof
SG10201408392PA (en) * 2009-01-15 2015-01-29 Lab Corp America Holdings Methods of determining patient response by measurement of her-3
MX2011009729A (en) 2009-03-20 2011-10-14 Genentech Inc Bispecific anti-her antibodies.
CA2759792A1 (en) 2009-04-29 2010-11-04 Trellis Bioscience, Inc. Improved antibodies immunoreactive with heregulin-coupled her3
AU2010249046A1 (en) 2009-05-13 2011-12-01 Sea Lane Biotechnologies, Llc Neutralizing molecules to influenza viruses
SG176073A1 (en) 2009-05-29 2011-12-29 Hoffmann La Roche Modulators for her2 signaling in her2 expressing patients with gastric cancer
US9050341B2 (en) * 2009-07-14 2015-06-09 Natco Pharma Limited Methods of treating drug resistant and other tumors by administering 6,7-dialkoxy quinazoline derivatives
WO2011047180A1 (en) 2009-10-14 2011-04-21 Merrimack Pharmaceuticals, Inc. Bispecific binding agents targeting igf-1r and erbb3 signalling and uses thereof
EP3351558B1 (en) * 2009-11-13 2020-03-11 Daiichi Sankyo Europe GmbH Material and methods for treating or preventing her-3 associated diseases
KR20120123299A (en) 2009-12-04 2012-11-08 제넨테크, 인크. Multispecific antibodies, antibody analogs, compositions, and methods
US8859737B2 (en) 2009-12-22 2014-10-14 Roche Glycart Ag Anti-HER3 antibodies and uses thereof
ES2535503T3 (en) 2010-03-11 2015-05-12 Merrimack Pharmaceuticals, Inc. Use of ErbB3 inhibitors in the treatment of triple negative breast cancer
RU2568051C2 (en) 2010-04-09 2015-11-10 Авео Фармасьютикалз, Инк. ANTI-ErbB3 ANTIBODIES
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
US8741288B2 (en) * 2010-07-07 2014-06-03 Chang Gung Medical Foundation, Linkou Branch Protein markers for detecting liver cancer and method for identifying the markers thereof
MY162825A (en) 2010-08-20 2017-07-31 Novartis Ag Antibodies for epidermal growth factor receptor 3 (her3)
TW201302793A (en) 2010-09-03 2013-01-16 Glaxo Group Ltd Novel antigen binding proteins
JP5766296B2 (en) 2010-12-23 2015-08-19 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Polypeptide-polynucleotide complexes and their use in targeted delivery of effector components
CA2828075A1 (en) 2011-03-11 2012-09-20 Merrimack Pharmaceuticals, Inc. Use of inhibitors of egfr-family receptors in the treatment of hormone refractory breast cancers
MX336197B (en) 2011-04-19 2016-01-11 Merrimack Pharmaceuticals Inc Monospecific and bispecific anti-igf-1r and anti-erbb3 antibodies.
EP2707391B1 (en) 2011-05-13 2017-11-08 Gamamabs Pharma Antibodies against her3
SG194609A1 (en) 2011-05-19 2013-12-30 Lab Corp America Holdings Methods for determining the likelihood of survival and for predicting likelihood of metastasis in cancer patients
WO2012176779A1 (en) 2011-06-20 2012-12-27 協和発酵キリン株式会社 Anti-erbb3 antibody
CA2842860A1 (en) 2011-07-28 2013-01-31 Sea Lane Biotechnologies, Llc Sur-binding proteins
JP6297490B2 (en) 2011-08-31 2018-03-20 ジェネンテック， インコーポレイテッド Diagnostic marker
US9273143B2 (en) 2011-09-30 2016-03-01 Regeneron Pharmaceuticals, Inc. Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibody
EP2760893B1 (en) 2011-09-30 2018-09-12 Regeneron Pharmaceuticals, Inc. Anti-erbb3 antibodies and uses thereof
CN108753942A (en) 2011-10-06 2018-11-06 Aveo制药公司 Predict the response of tumour confrontation ERBB3 antibody
IL309917A (en) 2011-10-14 2024-03-01 Genentech Inc Pertuzumab and Trastuzumab for use in therapy
JP6180425B2 (en) 2011-11-23 2017-08-23 メディミューン，エルエルシー Binding molecules specific for HER3 and their use
SG11201402510TA (en) 2011-11-30 2014-06-27 Genentech Inc Erbb3 mutations in cancer
EA201491107A1 (en) 2011-12-05 2014-11-28 Новартис Аг ANTIBODIES TO THE RECEPTOR EPIDERMAL GROWTH FACTOR 3 (HER3), DIRECTED TO DOMAIN II HER3
CN104159924B (en) 2011-12-05 2018-03-16 诺华股份有限公司 The antibody of EGF-R ELISA 3 (HER3)
WO2013083810A1 (en) 2011-12-09 2013-06-13 F. Hoffmann-La Roche Ag Identification of non-responders to her2 inhibitors
EP2793940B1 (en) 2011-12-22 2018-11-14 i2 Pharmaceuticals, Inc. Surrogate binding proteins
EP2817340B1 (en) 2012-02-23 2020-12-09 Daiichi Sankyo Europe GmbH Her3 inhibitor for modulating radiosensitivity
US20130259867A1 (en) 2012-03-27 2013-10-03 Genentech, Inc. Diagnosis and treatments relating to her3 inhibitors
WO2013152034A1 (en) 2012-04-02 2013-10-10 Merrimack Pharmaceuticals, Inc. Dosage and administration of monospecific and bispecific anti-igf-1r and anti-erbb3 antibodies
MX363188B (en) 2012-11-30 2019-03-13 Hoffmann La Roche Identification of patients in need of pd-l1 inhibitor cotherapy.
US9180185B2 (en) 2013-01-11 2015-11-10 Hoffman-La Roche Inc. Combination therapy of anti-HER3 antibodies
EP2954068B8 (en) 2013-02-05 2018-10-31 Pierian Holdings, Inc. Drug selection for non-small cell lung cancer therapy
PT2956476T (en) 2013-02-18 2020-02-21 Vegenics Pty Ltd Ligand binding molecules and uses thereof
EP2981828A1 (en) 2013-04-05 2016-02-10 Laboratory Corporation of America Holdings Systems and methods for facilitating diagnosis, prognosis and treatment of cancer based on detection of her3 activation
EP2994164B1 (en) 2013-05-08 2020-08-05 Zymeworks Inc. Bispecific her2 and her3 antigen binding constructs
WO2015048008A2 (en) 2013-09-24 2015-04-02 Medimmune, Llc Binding molecules specific for her3 and uses thereof
EP3087394A2 (en) 2013-12-27 2016-11-02 Merrimack Pharmaceuticals, Inc. Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies
MA39776A (en) 2014-03-24 2017-02-01 Hoffmann La Roche Cancer treatment with c-met antagonists and correlation of the latter with hgf expression
SG10201907807XA (en) 2014-04-10 2019-09-27 Daiichi Sankyo Co Ltd Anti-her3 antibody-drug conjugate
US10745490B2 (en) 2014-04-11 2020-08-18 Celldex Therapeutics, Inc. Anti-ErbB antibodies and methods of use thereof
ES2729202T3 (en) 2014-07-16 2019-10-30 Dana Farber Cancer Inst Inc Et Al Inhibition of HER3 in low grade serous ovarian cancers
JP2017528430A (en) 2014-07-17 2017-09-28 ブライアン ジェイ ツェルニキＣＺＥＲＮＩＥＣＫＩ， Ｂｒｉａｎ， Ｊ． Identification of immunogenic MHC class II peptides for immune-based therapy
ES2784900T3 (en) 2014-12-12 2020-10-01 Massachusetts Gen Hospital Treatment of brain metastases from breast cancer
AU2016271138A1 (en) 2015-05-29 2017-12-07 Merrimack Pharmaceuticals, Inc. Combination cancer therapies
US10184006B2 (en) 2015-06-04 2019-01-22 Merrimack Pharmaceuticals, Inc. Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
JP6787890B2 (en) 2015-06-29 2020-11-18 第一三共株式会社 Method for selective production of antibody-drug conjugate
EP3325005A4 (en) * 2015-07-17 2019-03-27 Brian J. Czerniecki Identification of immunogenic mhc class ii peptides for immune-based therapy
WO2017127545A1 (en) 2016-01-19 2017-07-27 Merrimack Pharmaceuticals, Inc. Dosage and administration of combination therapies comprising istiratumab, uses and methods of treatment
WO2017160990A1 (en) 2016-03-15 2017-09-21 Merrimack Pharmaceuticals, Inc. Methods for treating er+, her2-, hrg+ breast cancer using combination therapies comprising an anti-erbb3 antibody
WO2017194554A1 (en) 2016-05-10 2017-11-16 Inserm (Institut National De La Sante Et De La Recherche Medicale) Combinations therapies for the treatment of cancer
WO2018110515A1 (en) 2016-12-12 2018-06-21 第一三共株式会社 Combination of antibody-drug conjugate and immune checkpoint inhibitor
AU2017387909A1 (en) 2016-12-28 2019-06-27 Genentech, Inc. Treatment of advanced HER2 expressing cancer
MA47313B1 (en) 2017-01-17 2020-12-31 Hoffmann La Roche Her2 antibody subcutaneous formulations
AU2018210081A1 (en) 2017-01-17 2019-08-08 Daiichi Sankyo Company, Limited Anti-GPR20 antibody and anti-GPR20 antibody-drug conjugate
US11077189B2 (en) 2017-03-02 2021-08-03 Genentech Inc. Adjuvant treatment of HER2-positive breast cancer
KR20190140952A (en) 2017-04-24 2019-12-20 제넨테크, 인크. ERBB2 / HER2 mutations in transmembrane and proximal membrane domains
TW202330036A (en) 2017-05-15 2023-08-01 日商第一三共股份有限公司 Manufacturing method of antibody-drug conjugates
US11116827B2 (en) 2017-06-02 2021-09-14 Etubics Corporation Compositions and methods for tumor vaccination and immunotherapy involving HER antigens
CA3073924C (en) 2017-08-31 2023-10-17 Daiichi Sankyo Company, Limited Improved method for producing antibody-drug conjugate
CN117865839A (en) 2017-08-31 2024-04-12 第一三共株式会社 New method for preparing antibody-drug conjugate
CA3100745A1 (en) 2018-05-18 2019-11-21 Glycotope Gmbh Anti-muc1 antibody
BR112022026888A2 (en) 2020-06-29 2023-03-14 Genentech Inc METHODS OF TREATMENT OF HER2-POSITIVE CANCER IN A PATIENT, OF NEOADJUVANT THERAPY OF PATIENTS WITH HER2-POSITIVE EARLY BREAST CANCER AND OF NEOADJUVANT THERAPY OF HER2-POSITIVE EARLY BREAST CANCER AND METHOD FOR TREATMENT OF A PATIENT WITH HER2-POSITIVE CANCER
EP4180061A1 (en) 2021-11-10 2023-05-17 Nerviano Medical Sciences S.r.l. Anthracycline derivative linker reagents, antibody-drug conjugates and methods

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4867973A (en) * 1984-08-31 1989-09-19 Cytogen Corporation Antibody-therapeutic agent conjugates
US4480968A (en) * 1984-04-05 1984-11-06 General Motors Corporation Two-cycle engine compressor
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) * 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
GB8810400D0 (en) * 1988-05-03 1988-06-08 Southern E Analysing polynucleotide sequences
GB8910977D0 (en) 1989-05-12 1989-06-28 Rolls Royce Plc Metal matrix composite material
US5183884A (en) * 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
EP0444961A1 (en) * 1990-03-02 1991-09-04 Bristol-Myers Squibb Company Her3: A novel EGF receptor homolog

Also Published As

Publication number Publication date
JPH06503467A (en) 1994-04-21
CA2069900C (en) 2004-07-27
DK0502927T3 (en) 1998-06-02
ES2113877T3 (en) 1998-05-16
AU654805B2 (en) 1994-11-24
EP0502927B1 (en) 1998-03-11
ATE163970T1 (en) 1998-03-15
JP3196079B2 (en) 2001-08-06
US5820859A (en) 1998-10-13
WO1991008214A1 (en) 1991-06-13
US6639060B1 (en) 2003-10-28
EP0502927A4 (en) 1993-05-26
JP3632171B2 (en) 2005-03-23
JP2001299373A (en) 2001-10-30
US20040063140A1 (en) 2004-04-01
US5480968A (en) 1996-01-02
AU6889991A (en) 1991-06-26
DE69032133T2 (en) 1998-07-02
US5183884A (en) 1993-02-02
DE69032133D1 (en) 1998-04-16
EP0502927A1 (en) 1992-09-16
US5916755A (en) 1999-06-29

Similar Documents

Publication Publication Date Title
CA2069900A1 (en) Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
Kwong et al. A novel splice variant of HER2 with increased transformation activity
Fedele et al. Truncated and chimeric HMGI-C genes induce neoplastic transformation of NIH3T3 murine fibroblasts
Chang et al. Ligands for ErbB-family receptors encoded by a neuregulin-like gene
US5650285A (en) Human CRIPTO-related gene and method of measuring CR-3
Carlomagno et al. Molecular heterogeneity of RET loss of function in Hirschsprung's disease.
Franzen et al. Cloning of a TGFβ type I receptor that forms a heteromeric complex with the TGFβ type II receptor
Nakagawara et al. Cloning and chromosomal localization of the human TRK-B tyrosine kinase receptor gene (NTRK2)
Castiglioni et al. Role of exon-16-deleted HER2 in breast carcinomas
Nanni et al. p185neu protein is required for tumor and anchorage‐independent growth, not for cell proliferation of transgenic mammary carcinoma
Bussemakers et al. Molecular cloning and characterization of the human E-cadherin cDNA
Jia et al. The proto-oncogene of v-eyk (v-ryk) is a novel receptor-type protein tyrosine kinase with extracellular Ig/GN-III domains.
Graham et al. Cloning and developmental expression analysis of the murine c-mer tyrosine kinase
Yu et al. Adenovirus type 5 E1A gene products act as transformation suppressors of the neu oncogene
Pei et al. Isolation and characterization of a pituitary tumor-transforming gene (PTTG)
Lehväslaiho et al. A chimeric EGF‐R‐neu proto‐oncogene allows EGF to regulate neu tyrosine kinase and cell transformation.
Hudson et al. Structure and inducible regulation of the human c-erb B2/neu promoter.
Child et al. Cell type-dependent and-independent control of HER-2/neu translation
Tommasi et al. Molecular and functional characteristics of erbB2 in normal and cancer breast cells
Pilz et al. Comparative mapping of 50 human chromosome 9 loci in the laboratory mouse
Kottickal et al. Preferential expression of HMGI-C isoforms lacking the acidic carboxy terminal in human leukemia
Zoll et al. Alterations of the c-erbB2 gene in human breast cancer
Milisavljevic et al. Close linkage of the two keratin gene clusters in the human genome
Afrakhte et al. Production of cell‐associated PDGF‐AA by a human sarcoma cell line: evidence for a latent autocrine effect
Lehtola et al. A chimeric EGFR/neu receptor in functional analysis of the neu oncoprotein

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry